Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse payments to delay cheaper generics of Pomalyst.

Cigna sued Bristol Myers on Tuesday, accusing the drugmaker of violating federal antitrust law by maintaining a monopoly over ...

Pomalyst can cause certain adverse effects (side effects), some of which are more common than others. These side effects may be temporary, lasting a few days to weeks. But if the side effects last ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...

Cigna (NYSE:CI) on Tuesday filed an antitrust lawsuit accusing Bristol Myers Squibb (NYSE:BMY) of breaching U.S. competition rules by maintaining a monopoly over its blockbuster blood cancer  drug ...

Two months after Bristol Myers Squibb fended off a lawsuit which accused the drugmaker of using illegal tactics to protect ...

Insurance company Cigna claims Bristol Myers Squibb may have caused overpayments of ‘billions’ of dollars after allegedly ...

Pomalyst will be available in 1mg, 2mg, 3mg, and 4mg strength capsules in 21- and 100-count bottles. Pomalyst is expected to be available in about two weeks. Continue Reading.

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...

Pomalyst is a top seller for Bristol Myers, bringing in nearly $3.5 billion out of $46.16 billion of its total revenue last year. The company in July forecast sales of the drug to fall this year, ...

Pomalyst plus Velcade with dexamethasone improves survival outcomes for patients with relapsed/refractory multiple myeloma, according to a phase 3 trial. News. Cancer Horizons All News Blogs ...

Bristol Myers Squibb acquired Pomalyst when it purchased Celgene for $74 billion (₹6.15 lakh crore) in 2019. In 2022, Pomalyst generated nearly $3.5 billion (₹30,000 crore) in revenue, marking ...